Descrizione
Chromatin immunoprecipitation data showing DNMT1 enrichment at the CES1 promoter in 22RV1 and C4-2 cells, with melatonin decreasing this enrichment in a dose-dependent manner, indicating MLT suppresses DNA methylation of CES1.
Figure 19
ChartSource Paper
Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.Cite This Figure
![Figure 19: Chromatin immunoprecipitation data showing DNMT1 enrichment at the CES1 promoter in 22RV1 and C4-2 cells, with melatonin decreasing this enrichment in a dose-dependent manner, indicating MLT suppresses DNA methylation of CES1.]() > Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)
<figure> <img src="" alt="Chromatin immunoprecipitation data showing DNMT1 enrichment at the CES1 promoter in 22RV1 and C4-2 cells, with melatonin decreasing this enrichment in a dose-dependent manner, indicating MLT suppresses DNA methylation of CES1." /> <figcaption>Figure 19. Chromatin immunoprecipitation data showing DNMT1 enrichment at the CES1 promoter in 22RV1 and C4-2 cells, with melatonin decreasing this enrichment in a dose-dependent manner, indicating MLT suppresses DNA methylation of CES1.<br> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption> </figure>